US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

LivaNova PLC - Ordinary Shares (NQ:LIVN)

74.93 -1.50 (-1.96%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about LivaNova PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
LivaNova PLC (NASDAQ:LIVN): An Undervalued Opportunity in Medical Technology ↗
LivaNova PLC (NASDAQ:LIVN): An Undervalued Opportunity in Medical Technology 
Via Chartmill
News headline image
In a market where value is scarce, LIVANOVA PLC (NASDAQ:LIVN) offers a refreshing opportunity with its solid fundamentals. ↗
When you look at LIVANOVA PLC (NASDAQ:LIVN), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
LivaNova to Announce First-Quarter 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
NASDAQ:LIVN appears to be flying under the radar despite its strong fundamentals. ↗
Discover LIVANOVA PLC, an undervalued stock. NASDAQ:LIVN showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
News headline image
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
LivaNova to Present at the Barclays Global Healthcare Conference
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
From LivaNova PLC
Via Business Wire
News headline image
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Reports Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Susan Podlogar as a New Director
From LivaNova PLC
Via Business Wire
News headline image
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts ↗
LivaNova gets Buy rating from Goldman Sachs analyst. $65 PT. The company appears poised for consistent revenue growth in its base business. 
Via Benzinga
News headline image
LivaNova to Announce Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
LivaNova to Present at the Baird Global Healthcare Conference
From LivaNova PLC
Via Business Wire
News headline image
LIVN Stock Earnings: LivaNova Beats EPS, Beats Revenue for Q2 2024 ↗
LIVN stock results show that LivaNova beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
LivaNova Reports Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at the Goldman Sachs Healthcare Conference
From LivaNova PLC
Via Business Wire
News headline image
LIVN Stock Earnings: LivaNova Beats EPS, Beats Revenue for Q1 2024 ↗
LIVN stock results show that LivaNova beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
LivaNova Reports First-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
From LivaNova PLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >